Annual Total Liabilities
$88.86 M
+$4.87 M+5.80%
31 December 2023
Summary:
EyePoint Pharmaceuticals annual total liabilities is currently $88.86 million, with the most recent change of +$4.87 million (+5.80%) on 31 December 2023. During the last 3 years, it has risen by +$15.69 million (+21.43%). EYPT annual total liabilities is now at all-time high.EYPT Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$82.18 M
-$13.76 M-14.34%
30 September 2024
Summary:
EyePoint Pharmaceuticals quarterly total liabilities is currently $82.18 million, with the most recent change of -$13.76 million (-14.34%) on 30 September 2024. Over the past year, it has dropped by -$19.24 million (-18.97%). EYPT quarterly total liabilities is now -30.58% below its all-time high of $118.39 million, reached on 30 June 2023.EYPT Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EYPT Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +5.8% | -19.0% |
| 3 y3 years | +21.4% | +8.8% |
| 5 y5 years | +119.2% | +30.2% |
EYPT Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +21.4% | -30.6% | +8.8% |
| 5 y | 5 years | at high | +119.2% | -30.6% | +30.2% |
| alltime | all time | at high | >+9999.0% | -30.6% | >+9999.0% |
EyePoint Pharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $82.18 M(-14.3%) |
| June 2024 | - | $95.94 M(+21.0%) |
| Mar 2024 | - | $79.31 M(-10.7%) |
| Dec 2023 | $88.86 M(+5.8%) | $88.86 M(-12.4%) |
| Sept 2023 | - | $101.42 M(-14.3%) |
| June 2023 | - | $118.39 M(+55.4%) |
| Mar 2023 | - | $76.20 M(-9.3%) |
| Dec 2022 | $83.99 M(+6.3%) | $83.99 M(-0.2%) |
| Sept 2022 | - | $84.14 M(+2.5%) |
| June 2022 | - | $82.07 M(+5.6%) |
| Mar 2022 | - | $77.74 M(-1.6%) |
| Dec 2021 | $78.99 M(+7.9%) | $78.99 M(+4.6%) |
| Sept 2021 | - | $75.50 M(+4.9%) |
| June 2021 | - | $71.96 M(+0.7%) |
| Mar 2021 | - | $71.43 M(-2.4%) |
| Dec 2020 | $73.18 M(+13.2%) | $73.18 M(+5.8%) |
| Sept 2020 | - | $69.20 M(+5.6%) |
| June 2020 | - | $65.50 M(+2.6%) |
| Mar 2020 | - | $63.82 M(-1.3%) |
| Dec 2019 | $64.64 M(+59.5%) | $64.64 M(+2.4%) |
| Sept 2019 | - | $63.13 M(+0.0%) |
| June 2019 | - | $63.12 M(+1.8%) |
| Mar 2019 | - | $61.98 M(+50.6%) |
| Dec 2018 | $40.53 M(-32.4%) | - |
| Sept 2018 | - | $41.15 M(-31.4%) |
| June 2018 | $59.98 M(+1023.1%) | $59.98 M(+43.0%) |
| Mar 2018 | - | $41.96 M(+877.6%) |
| Dec 2017 | - | $4.29 M(-0.8%) |
| Sept 2017 | - | $4.33 M(-19.0%) |
| June 2017 | $5.34 M(-50.3%) | $5.34 M(+6.9%) |
| Mar 2017 | - | $5.00 M(+0.2%) |
| Dec 2016 | - | $4.98 M(-52.5%) |
| Sept 2016 | - | $10.48 M(-2.4%) |
| June 2016 | $10.74 M(+19.3%) | $10.74 M(+11.7%) |
| Mar 2016 | - | $9.61 M(+0.9%) |
| Dec 2015 | - | $9.53 M(+10.3%) |
| Sept 2015 | - | $8.64 M(-4.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2015 | $9.00 M(+16.2%) | $9.00 M(+14.6%) |
| Mar 2015 | - | $7.86 M(-0.6%) |
| Dec 2014 | - | $7.91 M(-0.4%) |
| Sept 2014 | - | $7.94 M(+2.5%) |
| June 2014 | $7.75 M(-9.4%) | $7.75 M(+0.9%) |
| Mar 2014 | - | $7.67 M(-6.6%) |
| Dec 2013 | - | $8.22 M(-3.3%) |
| Sept 2013 | - | $8.50 M(-0.6%) |
| June 2013 | $8.55 M(+22.8%) | $8.55 M(+8.5%) |
| Mar 2013 | - | $7.88 M(+8.9%) |
| Dec 2012 | - | $7.23 M(+0.8%) |
| Sept 2012 | - | $7.18 M(+3.1%) |
| June 2012 | $6.96 M(-28.1%) | $6.96 M(-4.4%) |
| Mar 2012 | - | $7.28 M(+1.7%) |
| Dec 2011 | - | $7.16 M(-9.5%) |
| Sept 2011 | - | $7.91 M(-18.3%) |
| June 2011 | $9.68 M(-2.9%) | $9.68 M(-2.7%) |
| Mar 2011 | - | $9.95 M(+0.5%) |
| Sept 2010 | - | $9.89 M(-0.8%) |
| June 2010 | $9.97 M(-26.5%) | $9.97 M(-3.5%) |
| Mar 2010 | - | $10.34 M(+1.8%) |
| Dec 2009 | - | $10.15 M(-21.4%) |
| Sept 2009 | - | $12.92 M(-4.7%) |
| June 2009 | $13.56 M(-47.2%) | $13.56 M(-11.3%) |
| Mar 2009 | - | $15.28 M(-12.4%) |
| Dec 2008 | - | $17.44 M(-12.1%) |
| Sept 2008 | - | $19.84 M(-22.8%) |
| June 2008 | $25.71 M(+35.6%) | $25.71 M(-3.7%) |
| Mar 2008 | - | $26.70 M(+105.5%) |
| Dec 2007 | - | $12.99 M(-12.4%) |
| Sept 2007 | - | $14.83 M(-21.8%) |
| June 2007 | $18.96 M(-57.8%) | $18.96 M(-39.6%) |
| Dec 2006 | - | $31.40 M(-30.0%) |
| June 2006 | $44.89 M(+385.7%) | $44.89 M(+385.7%) |
| June 2005 | $9.24 M(+586.2%) | $9.24 M(+586.2%) |
| June 2004 | $1.35 M(+128.9%) | $1.35 M(+128.9%) |
| June 2003 | $588.40 K(+303.8%) | $588.40 K |
| June 2001 | $145.70 K | - |
FAQ
- What is EyePoint Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual total liabilities year-on-year change?
- What is EyePoint Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly total liabilities year-on-year change?
What is EyePoint Pharmaceuticals annual total liabilities?
The current annual total liabilities of EYPT is $88.86 M
What is the all time high annual total liabilities for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual total liabilities is $88.86 M
What is EyePoint Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, EYPT annual total liabilities has changed by +$4.87 M (+5.80%)
What is EyePoint Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of EYPT is $82.18 M
What is the all time high quarterly total liabilities for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly total liabilities is $118.39 M
What is EyePoint Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, EYPT quarterly total liabilities has changed by -$19.24 M (-18.97%)